in my opinion, opportunity can be found at the int
Post# of 148173
in this case, the 75 non-miTT are contradictory to the miTT as well as the Agresti, Yang, and Montefiore patients.
the intersection is the 75 non-miTT patients, where probably also exists a coherent reason for the fda's lack of EUA.